37743-18-3

Basic information

• Product Name: 3,3-Diphenyltetrahydrofuran-2-ylidene(dimethyl)ammonium bromide
• Synonyms: (3,3-DIPHENYLDIHYDROFURAN-2-YLIDINE)DIMETHYLAMMONIUM BROMIDE;3,3-Diphenyltetrahydrofuran-2-ylidene(dimethyl)ammonium bromide;DIHYDRO-N,N-DIMETHYL-3,3-DIPHENYL-2(3H)-FURANIMINIUM BROMIDE;(dihydro-3,3-diphenyl-3H-furan-2-ylidene)dimethylammonium bromide;Dimethyl-(3,3-Diphenyl-Tetrahydro-2-Furylidene)Ammonium Bromide;Dihydro-N,N-dimethyl-3,3-diphenyl-2-(3H)-furaminium bromide;Dimethyl-(tetrahydro-3,3-diphenyl-2-furylidene)-ammonium bromide;(3,3-DIPHENYLDIHYDROFURAN-2-YLIDIUM)AMMONIUM BROMIDE
• CAS NO: 37743-18-3
• Molecular Formula: Br*C₁₈H₂₀NO
• Molecular Weight: 346.27
• EINECS: 253-649-9
• Product Categories: Pharmaceutical Intermediates;Heterocycles series
• Mol File: 37743-18-3.mol
• Article Data: 10

Chemical Properties

• Melting Point: 174.2-177.4 °C
• Appearance: white to beige powder
• Density: 1.3296 (rough estimate)
• Vapor Pressure: 0.002-0.007Pa at 20-25℃
• Refractive Index: 1.5570 (estimate)
• Solubility: >500 g/L (20°C)
• Water Solubility: >500 g/L (20 ºC)
• CAS DataBase Reference: 3,3-Diphenyltetrahydrofuran-2-ylidene(dimethyl)ammonium bromide(CAS DataBase Reference)
• NIST Chemistry Reference: 3,3-Diphenyltetrahydrofuran-2-ylidene(dimethyl)ammonium bromide(37743-18-3)
• EPA Substance Registry System: 3,3-Diphenyltetrahydrofuran-2-ylidene(dimethyl)ammonium bromide(37743-18-3)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 68-22
• Safety Statements: 45-36/37
• HazardClass: IRRITANT
• Hazardous Substances Data: 37743-18-3(Hazardous Substances Data)

Usage

Chemical Properties

white to beige powder

InChI:InChI=1/C18H20NO/c1-19(2)17-18(13-14-20-17,15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12H,13-14H2,1-2H3/q+1

Upstream product

• 956-89-8 3,3-Diphenyl-dihydro-furan-2-one 
• 50650-44-7 4-bromo-2,2-diphenylbutyric acid chloride 
• 497-19-8 sodium carbonate 
• 37742-98-6 4-Bromo-2,2-diphenylbutyric acid 
• 124-40-3 dimethyl amine 

Downstream Products

• 386214-65-9 N,N-dimethyl-2,2-diphenyl-4-[4-(2-hydroxyphenyl)piperazin-1-yl]butanamide 
• 53179-11-6 loperamide 
• 94682-46-9 4-dimethylamino-N,N-dimethyl-2,2-diphenyl-butyramide 
• 697284-98-3 4-[4-(2-carbamoylmethyl-2H-tetrazol-5-yl)-4-phenyl-piperidin-1-yl]-N,N-dimethyl-2-2-diphenyl-butyramide 
• 697284-97-2 N,N-diphenyl-4-[4-phenyl-4-(2H-tetrazol-5-yl)-piperidin-1-yl]-butyramide 
• 116063-33-3 N,N-dimethyl-α,α-diphenyl-4-[[9-(2-pyridinylmethyl)-9H-purin-8-yl]amino]-1-piperidinebutanamide 
• 1021954-04-0 N,N-dimethyl-2,2-diphenyl-4-(4-(N-phenylpropionamido)piperidin-1-yl)butanamide 
• 37743-13-8 4-hydroxy-N,N-dimethyl-2,2-diphenylbutanamide 

Relevant articles and documents

A high-yield route to synthesize the P-glycoprotein radioligand [ 11C]N-desmethyl-loperamide and its parent radioligand [ 11C]loperamide

N-Desmethyl-loperamide and loperamide were synthesized from α,α-diphenyl-γ-butyrolactone and 4-(4-chlorophenyl)-4- hydroxypiperidine in five and four steps with 8% and 16% overall yield, respectively. The amide precursor was synthesized from 4-bromo-2,2- diphenylbutyronitrile and 4-(4-chlorophenyl)-4-hydroxypiperidine in 2 steps with 21-57% overall yield. [11C]N-Desmethyl-loperamide and [ 11C]loperamide were prepared from their corresponding amide precursor and N-desmethyl-loperamide with [11C]CH3OTf through N-[11C]methylation and isolated by HPLC combined with solid-phase extraction (SPE) in 20-30% and 10-15% radiochemical yields, respectively, based on [11C]CO2 and decay corrected to end of bombardment (EOB), with 370-740 GBq/μmol specific activity at EOB.

4-OXADIAZOLYL-PIPERIDINE COMPOUNDS AND USE THEREOF

4-Oxadiazolyl-piperidine compounds of formula (I) and (II), their compositions and use for the treatment of pain and diarrhoea.

Design and synthesis of 4-phenyl piperidine compounds targeting the mu receptor

Small molecule mu agonists based on the 4-phenyl piperidine scaffold were designed and synthesized to further investigate the therapeutic potential of loperamide analogs. The resulting compounds show excellent agonistic activity towards the human mu receptor with interesting SAR trends within the series. Small molecule mu agonists based on the 4-phenyl piperidine scaffold were designed and synthesized to further investigate the therapeutic potential of loperamide analogs. The resulting compounds show excellent agonistic activity towards the human mu receptor with interesting SAR trends within the series.